CODX · Co-Diagnostics Inc.
AI read · Good for CODX
The AI's read
Co-Diagnostics filed a dual 510(k)/CLIA waiver for its Flu A/B and RSV assay and reported Q2 revenue of $166,000 with lower opex. That submission is a step toward commercialization and could be company changing if cleared. Market barely moved, up 0.66%, while the stock is oversold with RSI 25.87 and trading near its 52-week low. That suggests the regulatory news is not fully priced in yet. Cash dropped to $3.6M, which raises execution risk and caps upside until funding or approvals arrive. We lean bullish because regulatory progress plus cost cuts creates asymmetric upside from here.